Clinical Trial Update: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating mesenchymal stem cell-delivered DNX-2401 for recurrent high-grade glioma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma
• Malignant Glioma

Drugs mentioned

• MSC-DNX-2401 (DNX-2401 (Delta-24-RGD) oncolytic adenovirus delivered by mesenchymal stem cells)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma | Phase 1 | Status: RECRUITING